azurrx biopharma aims to become a leader in developing non-systemic, recombinant protein therapies for the treatment of gastrointestinal diseases and related conditions. ms1819 recombinant lipase for exocrine pancreatic insufficiency is the lead development program with additional early stage research being conducted for the prevention of hospital-acquired infection. the company is headquartered in new york, ny, with scientific operations based in langlade, france.
Company profile
Ticker
FWBI
Exchange
Website
CEO
James Sapirstein
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
AzurRx BioPharma, Inc., BioPharma d'Azur, Inc.
SEC CIK
Corporate docs
Subsidiaries
First Wave Bio, Inc. • ImmunogenX, LLC ...
FWBI stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
29 Mar 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
22 Mar 24
8-K
First Wave BioPharma Announces Two Abstracts on Celiac Disease Research Accepted for Presentation at the 2024 Digestive Disease Week (DDW) Conference
18 Mar 24
DEFA14A
Additional proxy soliciting materials
18 Mar 24
DEFA14A
Additional proxy soliciting materials
14 Mar 24
8-K
Latiglutenase is a potentially first-in-class oral biotherapeutic for the treatment of celiac disease
14 Mar 24
8-K
First Wave BioPharma, Inc. to raise approximately $4.0 million of Gross Proceeds in Registered Direct Offering
5 Mar 24
424B5
Prospectus supplement for primary offering
4 Mar 24
424B3
Prospectus supplement
18 Jan 24
EFFECT
Notice of effectiveness
18 Jan 24
Transcripts
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 3.31 mm | 3.31 mm | 3.31 mm | 3.31 mm | 3.31 mm | 3.31 mm |
Cash burn (monthly) | (no burn) | (no burn) | 1.14 mm | 1.16 mm | 1.11 mm | 1.21 mm |
Cash used (since last report) | n/a | n/a | 7.63 mm | 7.75 mm | 7.40 mm | 8.07 mm |
Cash remaining | n/a | n/a | -4.31 mm | -4.44 mm | -4.09 mm | -4.76 mm |
Runway (months of cash) | n/a | n/a | -3.8 | -3.8 | -3.7 | -3.9 |
Institutional ownership, Q2 2023
2.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 11 |
Opened positions | 5 |
Closed positions | 2 |
Increased positions | 1 |
Reduced positions | 2 |
13F shares | Current |
---|---|
Total value | 60.11 mm |
Total shares | 47.45 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 16.48 k | $26.36 mm |
STT State Street | 11.80 k | $18.88 mm |
Acadian Asset Management | 9.89 k | $15.00 k |
Tower Research Capital | 7.65 k | $12.25 mm |
Advisor | 1.00 k | $1.60 mm |
BLK Blackrock | 397.00 | $636.00 k |
FMR | 158.00 | $253.00 k |
UBS UBS Group AG - Registered Shares | 29.00 | $46.00 k |
USB U.S. Bancorp. | 24.00 | $38.00 k |
Kathleen S. Wright Associates | 22.00 | $35.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Apr 24 | Romano Sarah | Common Stock | Sell | Dispose S | No | No | 4.2294 | 75 | 317.21 | 19,111 |
1 Apr 24 | Sapirstein James | Common Stock | Sell | Dispose S | No | No | 4.2294 | 174 | 735.92 | 37,105 |
15 Mar 24 | Sapirstein James | Common Stock | Sell | Dispose S | No | No | 4.96 | 1,887 | 9.36 k | 37,279 |
15 Mar 24 | Romano Sarah | Common Stock | Sell | Dispose S | No | No | 4.96 | 1,120 | 5.56 k | 19,186 |
News
HC Wainwright & Co. Reinstates Neutral on First Wave BioPharma
25 Mar 24
Roth MKM Maintains Buy on First Wave BioPharma, Lowers Price Target to $36
15 Mar 24
12 Health Care Stocks Moving In Friday's Pre-Market Session
15 Mar 24
Why Limbach Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
14 Mar 24
First Wave BioPharma Completes Merger Deal With ImmunogenX Adding Phase 3-Ready Candidate For Celiac Disease
14 Mar 24
Press releases
First Wave BioPharma CEO James Sapirstein to Present at the Planet MicroCap Showcase
17 Apr 24
First Wave BioPharma Announces Completion of Business Combination with ImmunogenX, Adding Phase 3-Ready Latiglutenase to its Late-Stage GI-Focused Clinical Pipeline
14 Mar 24
First Wave BioPharma, Inc. to Raise Approximately $4.0 Million of Gross Proceeds in Registered Direct Offering
4 Mar 24
First Wave BioPharma to Present at the DealFlow MicroCap Conference
23 Jan 24